4,449 Shares in Amedisys, Inc. (NASDAQ:AMED) Acquired by Engineers Gate Manager LP

Engineers Gate Manager LP purchased a new position in Amedisys, Inc. (NASDAQ:AMED – Get Rating) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 4,449 shares of the health services provider’s stock, valued at approximately $431,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in AMED. Raymond James & Associates grew its stake in shares of Amedisys by 6.5% in the 1st quarter. Raymond James & Associates now owns 11,101 shares of the health services provider’s stock worth $1,913,000 after buying an additional 680 shares during the last quarter. Raymond James Financial Services Advisors Inc. grew its stake in shares of Amedisys by 9.2% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 2,397 shares of the health services provider’s stock worth $413,000 after buying an additional 202 shares during the last quarter. Cambridge Investment Research Advisors Inc. grew its stake in shares of Amedisys by 22.1% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 3,425 shares of the health services provider’s stock worth $590,000 after buying an additional 620 shares during the last quarter. HighTower Advisors LLC grew its stake in shares of Amedisys by 40.4% in the 1st quarter. HighTower Advisors LLC now owns 7,619 shares of the health services provider’s stock worth $1,310,000 after buying an additional 2,193 shares during the last quarter. Finally, Citigroup Inc. grew its stake in shares of Amedisys by 6.4% in the 1st quarter. Citigroup Inc. now owns 13,268 shares of the health services provider’s stock worth $2,287,000 after buying an additional 803 shares during the last quarter. Hedge funds and other institutional investors own 96.17% of the company’s stock.

Insider Buying and Selling

In related news, insider Michael Paul North sold 5,908 shares of the firm’s stock in a transaction on Friday, March 3rd. The stock was sold at an average price of $86.43, for a total value of $510,628.44. Following the transaction, the insider now directly owns 4,164 shares of the company’s stock, valued at approximately $359,894.52. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 2.10% of the stock is owned by insiders.

Amedisys Price Performance

Shares of Amedisys stock opened at $82.56 on Monday. Amedisys, Inc. has a one year low of $79.30 and a one year high of $179.91. The stock’s fifty day moving average is $90.31 and its 200 day moving average is $94.85. The stock has a market cap of $2.69 billion, a P/E ratio of 22.68, a P/E/G ratio of 2.30 and a beta of 1.04. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.09 and a current ratio of 1.09.

Amedisys (NASDAQ:AMED – Get Rating) last announced its earnings results on Thursday, February 16th. The health services provider reported $1.16 EPS for the quarter, topping analysts’ consensus estimates of $1.03 by $0.13. Amedisys had a return on equity of 15.44% and a net margin of 5.34%. The company had revenue of $562.10 million for the quarter, compared to analysts’ expectations of $560.46 million. During the same period last year, the firm earned $1.18 EPS. Amedisys’s revenue for the quarter was up .5% compared to the same quarter last year. Sell-side analysts anticipate that Amedisys, Inc. will post 4.26 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Credit Suisse Group reaffirmed an “outperform” rating and issued a $115.00 price objective on shares of Amedisys in a research report on Monday, February 27th. SVB Leerink lowered their price objective on Amedisys from $96.00 to $85.00 and set a “market perform” rating on the stock in a research report on Thursday, January 5th. Stephens reaffirmed an “equal weight” rating and issued a $95.00 price objective on shares of Amedisys in a research report on Thursday, February 16th. Benchmark reaffirmed a “buy” rating and issued a $120.00 price objective on shares of Amedisys in a research report on Monday, February 13th. Finally, Oppenheimer lowered their price objective on Amedisys from $145.00 to $125.00 and set an “outperform” rating on the stock in a research report on Thursday, January 19th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $121.53.

About Amedisys

(Get Rating)

Amedisys, Inc engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery.